Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Chivalrous Knight Does Pro Bono

Abstract:
Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company"), a leading Canadian specialty pharmaceutical company, announced today that it has (1) extended a secured loan of US$15 million to Pro Bono Bio PLC ("Pro Bono Bio"), the world's leading healthcare nanotechnology company, and (2) entered into an exclusive distribution agreement with Pro Bono Bio to commercialize its wide range of nanotechnology products, medical devices and drug delivery technologies in select territories.

Chivalrous Knight Does Pro Bono

Montreal, Canada | Posted on June 27th, 2015

The secured loan of US$15 million, which matures on June 25, 2018, will bear interest at 12% per annum plus other additional consideration. The interest rate will decrease to 10% if Pro Bono Bio meets certain equity-fundraising targets. The loan is secured by a charge over the assets of Pro Bono Bio and its affiliates which includes but is not limited to Flexiseq™, an innovative topical pain product that has sales of more than 3 million units since its U.K. launch last year.

As part of the license agreement, Knight obtained the exclusive Quebec and Israeli distribution rights to Pro Bono Bio's innovative Flexiseq™ range of pain relief products and its promising SEQuaderma™ derma-cosmetic range of products, both of which are expected to launch in Quebec within the next 12 months. In addition, Knight obtained the exclusive Canadian and Israeli rights to two earlier stage product groups: blood factor products for the treatment of Hemophiliacs, and diagnostic devices designed for the automated detection of peripheral arterial disease.

John Mayo, Chairman and CEO of Pro Bono Bio, said, "We worked night and day to find a good distribution and strategic partner to help our North American team launch our existing products and drive growth. We welcome the good Knight on our quest to deliver to Canadian and American consumers' best-in-class, drug-free nanotechnology products that are safe, effective and of the highest quality: truly the holy grail!"

"When you donate to charity, you always receive back more than you give. I hope this truism also holds true for this Pro Bono world!" said Jonathan Ross Goodman, President and CEO of Knight. "We look forward to the late 2015 launch of Flexiseq™ and SEQuaderma™ in La Belle Province."

####

About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight's shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the Company's web site at www.gud-knight.com or www.sedar.com.

About Flexiseq™

Flexiseq™ is a topically applied drug-free gel which is clinically proven to safely relieve the pain and improve the joint stiffness associated with osteoarthritis (OA). Flexiseq™ is unique - it lubricates your joints to address joint damage. Pain is relieved and joint function improved because it lubricates away the friction and associated wear and tear on a user's joints.

About SEQuaderma™

SEQuaderma™ Dermatology Products are a unique range of active dermatology solutions specifically designed to address the symptoms and, in some cases, the causes of the targeted conditions, leading to reduced recurrence. SEQuaderma™ Dermatology Products are suitable for long term use and can be used on their own or in between drug treatments to reduce exposure to adverse events; they will not compromise any other medication and are suitable for those with multiple conditions.

About Pro Bono Bio PLC

Pro Bono Bio PLC is the world's leading healthcare nanotechnology company offering health and lifestyle products, headquartered in London with presence in Europe, Africa and Asia and due to launch in North America.

For more information, please click here

Contacts:
Knight Therapeutics Inc.
Jeffrey Kadanoff, P.Eng., MBA
Chief Financial Officer
514-484-GUD1 (4831)
514-481-4116 (FAX)

Copyright © Marketwire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

uSEE breakthrough unlocks the nanoscale world on standard biology lab equipment August 16th, 2019

Optofluidic chip with nanopore 'smart gate' developed for single molecule analysis: Programmable device enables on-demand delivery of individual biomolecules with feedback-controlled gating for high-throughput analysis August 16th, 2019

ULVAC Launches Revolutionary PZT Piezoelectric Thin-film Process Technology and HVM Solution for MEMS Sensors/Actuators: Enabling Reliable, High-quality Film Production for Next Generation Devices August 16th, 2019

RIT to upgrade Semiconductor and Microsystems Fabrication Laboratory through $1 million state grant: Upgrades to clean room will enhance university’s research capabilities in photonics, quantum technologies and smart systems August 16th, 2019

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

180 Degree Capital Corp.’s Portfolio Company, TheStreet, Inc., Enters into Agreement to be Acquired by TheMaven, Inc. for $16.5 Million June 13th, 2019

180 Degree Capital Corp. Reports Net Asset Value per Share of $2.76 as of March 31, 2019; an Increase of 4.5% From December 31, 2018 May 1st, 2019

180 Degree Capital Corp. to Report First Quarter 2019 Financial Results on Wednesday, May 1, 2019 and to Host a Conference Call on Thursday, May 2, 2019 April 26th, 2019

A Nanobiotechnology Startup from a small town in India attracts the Global Investors January 27th, 2019

Nanomedicine

uSEE breakthrough unlocks the nanoscale world on standard biology lab equipment August 16th, 2019

Optofluidic chip with nanopore 'smart gate' developed for single molecule analysis: Programmable device enables on-demand delivery of individual biomolecules with feedback-controlled gating for high-throughput analysis August 16th, 2019

RIT to upgrade Semiconductor and Microsystems Fabrication Laboratory through $1 million state grant: Upgrades to clean room will enhance university’s research capabilities in photonics, quantum technologies and smart systems August 16th, 2019

Probing the Origin of Alzheimer’s . . . with Transistors: Novel high-sensitivity detector could aid in early diagnosis August 15th, 2019

Announcements

uSEE breakthrough unlocks the nanoscale world on standard biology lab equipment August 16th, 2019

Optofluidic chip with nanopore 'smart gate' developed for single molecule analysis: Programmable device enables on-demand delivery of individual biomolecules with feedback-controlled gating for high-throughput analysis August 16th, 2019

ULVAC Launches Revolutionary PZT Piezoelectric Thin-film Process Technology and HVM Solution for MEMS Sensors/Actuators: Enabling Reliable, High-quality Film Production for Next Generation Devices August 16th, 2019

RIT to upgrade Semiconductor and Microsystems Fabrication Laboratory through $1 million state grant: Upgrades to clean room will enhance university’s research capabilities in photonics, quantum technologies and smart systems August 16th, 2019

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project